Four Star
Concise Prescribing Info
NIDDM in patients inadequately controlled on diet alone, or on diet & oral hypoglycaemic agents. Prevention of onset of NIDDM in patients w/ impaired glucose tolerance & impaired fasting glycaemia, in combination w/ diet & exercise.
Dosage/Direction for Use
Adult Treatment Initially 50 mg tds, may be increased to 100 mg tds after 6-8 wk, if necessary. Max dose: 200 mg tds. To minimize GI side-effects, initially 50 mg once daily or bd, titrated to tds regimen. Prevention Initially 50 mg daily, subsequently increased to 100 mg tds after 4-8 wk. Patient w/ ≤60 kg body wt 50 mg tds.
Should be taken with food: Take w/ 1st bite of a main meal.
Hypersensitivity. Patients w/ inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or patients predisposed to intestinal obstruction; chronic intestinal diseases associated w/ marked disorders of digestion or absorption; conditions which may deteriorate as a result of increased gas formation in the intestine (eg, larger hernias). Severe hepatic impairment. Severe renal impairment (CrCl <25 mL/min/1.73 m2). Pregnancy & lactation.
Special Precautions
Risk of hypoglycaemia w/ other blood glucose lowering drugs (eg, sulphonylureas: metformin, or insulin); should not be corrected using disaccharides (sucrose). Consider liver enzyme monitoring during the 1st 6-12 mth of treatment. Reduce dose or discontinue use in case of persistent liver enzyme elevations. Use of Mg- & Al-containing antacid prep (eg, hydrotalcite) to treat acute GI symptoms of Glucobay is not recommended. Childn & adolescents <18 yr.
Adverse Reactions
Flatulence. Diarrhoea, GI & abdominal pain.
Drug Interactions
Potentiated hypoglycaemic effects of insulin, metformin & sulphonylurea drugs. Delayed digestion & absorption of disaccharides (eg, sucrose). Abdominal discomfort or diarrhoea w/ sucrose & foods containing sucrose. Reduced effect w/ intestinal adsorbents (eg, charcoal) & digestive enzyme prep containing carbohydrate splitting enzymes (eg, amylase, pancreatin). Enhanced postprandial blood glucose reduction & increased frequency & severity of GI side effects w/ neomycin. Enhanced postprandial insulin level reduction w/ cholestyramine. My affect digoxin bioavailability.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BF01 - acarbose ; Belongs to the class of alpha glucosidase inhibitors. Used in the treatment of diabetes.
Glucobay tab 100 mg
Glucobay tab 50 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in